What was the peptide community discussing from 14 to 20 September 2026, and how much of it holds up?

The short answer

BPC-157 took over the peptide conversation last week. Mentions rose 44% and the single most-shared post of the week — 613 likes, 28,527 views — listed five injuries the peptide supposedly healed: a severed Achilles, a crushed spinal cord, a knee ligament, a hole in an eyeball, a section of bone sawed out.

We checked all five. Every one traces to a real, published, peer-reviewed study. Four are in rats. The fifth is in rabbits. None is in humans, the post does not say so, and it ends with a link to buy.

That is the week's shape in miniature: the underlying science is usually real, and the description of it is usually wrong in a specific, load-bearing way.

Two other things happened that matter more than the volume. A large account told its audience that dihexa "has good humans safety data" — dihexa has no human data of any kind, and the three papers that established its proposed mechanism were retracted in April 2025 for image manipulation. And a properly powered, randomised, placebo-controlled Phase 2 trial of BPC-157 in hamstring injury is now recruiting, with an MRI endpoint. After thirty years of rat studies, that is the first thing in this space that could actually settle an argument.

What got discussed, and how much

138 Reddit posts and 172 X posts, 14–20 September.

New entrants with no mentions the week before: orforglipron (3), CagriSema (2), SNAP-8, kisspeptin, AOD-9604 (1 each).

Two of those movements are worth pausing on.

Semaglutide's +178% is one man. Bryan Johnson posted a breakdown of the Nature longevity paper on 18 September — 520 likes, 50,723 views — and David Sinclair asked "Are GLP-1 meds longevity drugs in disguise?" two days later. Neither is new science. The paper came out on 2 September and we wrote about it then. This is a second wave of the same study, which is what a longevity news cycle looks like.

Tesamorelin's −67% happened the week we published on it, and we do not flatter ourselves that those are connected. More likely both reflect the same decay: the compound had its news cycle and lost it. But it did not disappear — it came back inside a new package, discussed below.

A caveat on the Reddit numbers. 124 of our 138 Reddit posts came from r/Mounjaro and only about 14 from r/Peptides. Our ingest is weighted toward GLP-1 communities, so tirzepatide's dominance is partly an artefact of where we look. The X corpus is the better guide to what the wider peptide community is discussing; Reddit is the better guide to what GLP-1 patients are actually experiencing. Read the two halves of this article accordingly.

The BPC-157 post, claim by claim

Here is the full accounting. Every PMID below was verified against PubMed.

Three of those five are misstated in ways that change the meaning, not just the register.

A 2-mm corneal incision is not a hole in an eyeball, and a negative leak test at 24 hours is not healing — the cornea took three to four days to close. The spinal cord model produces tail paralysis in the sacrocaudal segment, not the paraplegia that "crushed spinal cord" conjures; and reading "healing at day 360" as slow, grinding recovery inverts the design, where day 360 was simply the last day the researchers checked and found the recovery had held.

The Achilles and bone claims are, in fairness, close to what the original authors themselves wrote. The 1999 rabbit paper's own conclusion is that BPC-157 matched autologous bone grafting. Our objection there is not distortion; it is that a single unreplicated 1999 rabbit study is being offered as a reason to inject yourself.

The claim in that post that is simply false

"fifteen amino acids. your stomach makes them right now."

The first half is true. BPC-157 is 15 residues, GEPPPGKPADDAGLV, about 1419 Da.

The second half is not. BPC-157 is a synthetic peptide whose sequence corresponds to a fragment of a putative larger "body protection compound" reported to have been isolated from human gastric juice by one Zagreb laboratory in the early 1990s. That parent protein has never been characterised. There is no identified human gene for it. There is no published detection of the free 15-mer in human gastric juice, plasma or tissue. USADA states the position plainly: the BPC-157 sold online and through compounding pharmacies "is all synthetically produced."

We are not claiming no such protein exists — that is unproven either way. What is false is the affirmative statement that your body is making this peptide right now. It is the load-bearing rhetorical move in the whole post, because "your stomach already makes it" is what converts an unapproved research chemical into something that sounds endogenous and therefore safe.

The thing about BPC-157 that almost never gets said

Of 222 PubMed records mentioning BPC-157, PL 14736 or the full name, 172 — 77% — list Sikiric P as an author. Include Seiwerth S and it is 79%. Only 21% have neither.

An independent 2026 review in Pharmaceutics puts it at "exceeding 80% by author affiliation analysis" and names the consequence directly: "the absence of independent replication across geographically and institutionally diverse laboratories" (Enache A. 2026. Pharmaceutics 18(5):625. PMID 42198317).

Independent work does exist — a Chinese group produced the first ADME data generated outside Zagreb, and there are recent Turkish, Polish and Gazi University papers. But none of the five flagship results above has been reproduced by an independent laboratory. The evidence base is not thin because nobody has looked. It is concentrated because mostly one group has looked.

Human evidence: under 30 people, no controls

Thirty people, three uncontrolled reports, one journal, one Florida clinic, and not one objective healing endpoint among them. Two independent 2025–26 reviews reach the same conclusion (PMID 40789979, PMID 42198317).

A note for anyone who has read that BPC-157 is "in clinical trials for IBD as PL 14736": we could find no PubMed-indexed publication of any PL 14736 human trial and no ClinicalTrials.gov record for it. Treat those results as unpublished and uncitable.

What is genuinely new: a real trial is recruiting

This is the most consequential thing we found all week, and nobody was posting about it.

NCT07437547 — Hudson Biotech, Phase 2, randomised, double-blind, placebo-controlled. Acute grade II hamstring strain, n=120 estimated. Started February 2026, completion February 2027. Co-primary endpoints: time to return to sport, and MRI injury volume at day 14.

That is the first adequately powered BPC-157 healing trial with an objective imaging endpoint in the compound's thirty-year history. A second, NCT07803250 (University of Arkansas, Phase 1 pilot after arthroscopic rotator cuff repair, n=30), is due to start January 2027 — and its own registry record states that BPC-157 "has not yet been studied in formal human clinical trials."

If you want to know whether BPC-157 heals tissue in humans, the answer arrives in about eighteen months. Until then, anyone telling you it does is extrapolating from rats.

For completeness: BPC-157 sits on WADA's S0 Non-Approved Substances list, prohibited at all times, and is not approved by any health authority.

The heart-restart post

The same account posted this two days later, 58 likes:

"Researchers STOPPED a heart with the drug used on death row. Then a stomach peptide BROUGHT IT BACK... They stopped hearts three different ways. The peptide restarted them every time. (PMID: 23327997)"

The PMID is real and correctly transcribed, which is more than we can usually say. It is Barisic I, et al. 2013. "Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157." Regul Pept 181:50-66.

Read the title. It is rats, and it is hyperkalemia — potassium excess, which is indeed the mechanism by which potassium chloride is lethal. BPC-157 reduced arrhythmia and mortality in a rat model of potassium overload. That is a reasonable finding.

It is not researchers stopping a heart and a peptide restarting it. And "your gut makes this compound. Right now. While you read this" appears in this post too.

Dihexa: the week's most dangerous sentence

On 19 September, an account we have flagged before posted:

"dihexa gives me a short lasting version of photographic memory, seriously... i take dihexa quite often and will continue to do so, since its much safer than people believe and has good humans safety data as well."

Dihexa has no human data. None.

• ClinicalTrials.gov: 0 records for dihexa.
• PubMed: 18 records total. Not one is a human study, a human pharmacokinetic study, or a human safety or toxicology study. The records tagged "Humans" are in-vitro human-cell papers.
• No published carcinogenicity, genotoxicity, repeat-dose toxicology or ADME study in any species that we could locate.

This is not a case of thin data being oversold. There is nothing to oversell.

And the mechanism papers were retracted

We did not know this before this week. The foundational papers establishing dihexa's proposed HGF/c-Met mechanism were retracted in April 2025 for image manipulation:

The original dihexa design paper (McCoy AT, et al. 2013. JPET 344(1):141-54. PMID 23055539) carries a 2021 expression of concern and has not been retracted.

This creates a double bind that is worth stating carefully. The claim "dihexa works via HGF/c-Met" now rests on withdrawn papers. But that is not reassurance about the cancer question — it means the mechanism is simply uncharacterised. "It probably doesn't hit MET" is not a safety argument; it is an admission that nobody knows what it does.

Separately, and not to be confused with dihexa safety data: fosgonimeton, a different HGF/MET-pathway molecule from the same research lineage, was tested in humans and failed its Phase 2/3 LIFT-AD trial (n=315, missed primary endpoint, reported December 2023), plus a separate Phase 2 failure in dementia with Lewy bodies.

Why the MET question is not hypothetical

We flagged this in August and can now state it precisely. On 14 May 2025 the FDA granted accelerated approval to telisotuzumab vedotin-tllv (EMRELIS, AbbVie), a c-Met-directed antibody-drug conjugate, for adults with locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression — defined as ≥50% of tumour cells at 3+ staining — after prior systemic therapy. Basis: LUMINOSITY (NCT03539536), n=84, ORR 35%.

Eligibility turns on protein overexpression, not MET mutation or amplification. That is clinical validation that the sheer quantity of c-Met signalling capacity in tissue is oncologically meaningful on its own.

To be scrupulous: this is an argument about plausibility and unquantified risk. It is not evidence that dihexa causes cancer, and we are not saying it does. What we are saying is that a compound whose proposed mechanism is chronic potentiation of HGF/c-Met signalling, taken indefinitely by a healthy person, with zero toxicology in any species and no human data at all, is being described to a large audience as having "good human safety data." That sentence is false, and the gap between it and reality is the entire safety margin.

The same account also recommended cerebrolysin as countering "EVERY single neurotoxic side effect studied from tren" with "the other 1000+ benefits it brings." Cerebrolysin mentions rose 133% last week, almost entirely from this one account.

The Nature mouse paper, described well this time

Two weeks ago we wrote about people getting this study wrong. In fairness, we should report when someone gets it right.

Bryan Johnson's 18 September breakdown is broadly accurate and directionally correct on almost every endpoint, and the most sophisticated part — the calorie-restriction comparison — is close to what the paper reports. That is a real improvement on what circulated on 2 September.

The verified paper: Feng Y, Barthez M, Wang Y, et al. 2026. "Late-life semaglutide treatment slows ageing and extends lifespan in female mice." Nature 657(8131):469-476. PMID 42686906.

What holds up:

• +12% lifespan is correct — median 742 days (control) to 834 days, +92 days, Kaplan-Meier.
• Treatment started at 20 months, female C57BL/6 from the NIA, 10 nmol/kg/day subcutaneous. Correct. ("Human equivalent to 60s" is his gloss, not the paper's.)
• Female-only, and that is the paper's design, not an omission — the authors state females were chosen to minimise confounding from male aggression and injury. There is no male cohort, which is why "yes, if you're a female mouse" was never the gotcha it was presented as.
• The calorie-restriction arm is real. A separate cohort received vehicle, semaglutide, or 24% calorie restriction for 5 months, n=10 per group. CR matched semaglutide on open-field movement, elevated-plus-maze movement, rotarod, inverted screen and treadmill endurance. Semaglutide exceeded CR on open-field centre time, Barnes maze spatial memory, and glucose tolerance.

What does not hold up:

• "Bone marrow colonies +44%" is backwards. The paper reports colony-forming cells in the marrow were reduced, while colony size was bigger. Phenotypic HSC frequency also fell. The rejuvenation argument is more output per cell, not more colonies.
• "Hippocampal neurons ~3×" is mislabelled. Those are BrdU+ and DCX+ cells in the dentate gyrus — newly proliferating and immature cells, not total hippocampal neurons. n=5 pairs. And the finding is correlative: there is no ablation or knockout tying neurogenesis to the maze result.
• Eleven of the thirteen percentages appear nowhere in the paper's text. The article reports directions of change and figure callouts; the magnitudes live only in the figures and the Source Data spreadsheets. The numbers may well be right. They are not citable from the paper as published.
• "Control was a separate group on 24% food restriction" misstates the design. There were three arms and the control was vehicle-injected; CR was a comparator. And the 24% was matched to semaglutide's observed food-intake reduction, not titrated to reproduce weight loss — comparable fat loss was a result, not the design target.
• "Failed to match" overstates it. CR maintained exploratory drive, spatial memory and glucose control near baseline; semaglutide improved them above baseline. CR did not fail. It prevented decline without reversing it.

Also omitted: lifespan (n=39/40) and the functional endpoints (a separate cohort, 10 pairs) are different mice, so "lived 12% longer and ran 2.8× as long" splices two experiments. Molecular work used 6 pairs, neural stem cell work 5. Every percentage he quotes rests on 5–10 animals per group. And the NIH's own release on the paper states the findings do not show these drugs extend human lifespan.

"Leanmaxxing" and how tesamorelin came back

A new word appeared last week. On 19 September, 94 likes:

"Leanmaxxing is trending. Tirzepatide + Tesamorelin is the best legal peptide combo for cutting both subcutaneous fat (under the skin) + visceral fat (around the organs). Nothing shrinks your midsection more."

This is more interesting than the usual because half of it is right, and it is the half we wrote about last week.

Tesamorelin really is visceral-selective, and the evidence is good. Pooled phase 3 in 806 ART-treated patients: VAT fell 24 cm² versus +2 on placebo, a −15.4% treatment effect, p<0.001 — while abdominal subcutaneous fat did not significantly change (−2 vs +2 cm², p=0.08) (Falutz J, et al. 2010. J Clin Endocrinol Metab 95(9):4291-304. PMID 20554713). A 2026 meta-analysis confirms it: VAT −27.71 cm², no significant SAT or BMI reduction (PMID 41545261). And it replicates outside HIV — in 60 abdominally obese non-HIV subjects with reduced GH secretion, VAT fell 35 cm² over 12 months while SAT did not move (PMID 23015655).

So the community has absorbed the anatomy. Genuinely.

But the tirzepatide half is wrong, and it collapses the whole argument. Tirzepatide is not subcutaneous-selective. SURPASS-3's MRI substudy found it reduced liver fat and VAT and abdominal subcutaneous fat (PMID 35468325), and the SURMOUNT-1 DXA substudy found visceral fat mass and waist circumference both significantly reduced (PMID 39996356). Tirzepatide reduces both depots. The premise that it covers subcutaneous while tesamorelin covers visceral — the complementarity that makes the stack sound designed — is not true.

And then the parts that are plainly unsupported:

• There is no trial of the combination. ClinicalTrials.gov returns 24 tesamorelin studies and not one involves tirzepatide or any incretin agent. PubMed returns zero records for both terms together. The nearest paper is a two-case report explicitly describing tesamorelin and GLP-1 agonists as distinct therapeutic pathways (PMID 42139091).
• "Legal" is wrong for anyone drug-tested. Tesamorelin is a GHRH analogue and sits under WADA S2.2, prohibited at all times. (We could not open WADA's official 2026 list PDF — the site returns bot challenges on document paths — so we state this from mirrored sources; the S2.2 listing has been stable across years, but verify before relying on it.) Tesamorelin is also approved only for excess abdominal fat in HIV lipodystrophy, with a label that explicitly says it is not indicated for weight management. Cosmetic use is off-label.
• "Nothing shrinks your midsection more" is a superlative with no comparative trial behind it.

One correction to a claim circulating alongside this: we saw a vendor source assert GLP-1 agonists moved to WADA S4 prohibition in January 2026. WADA's own announcement of the 2026 list itemises the modifications and contains no such addition. Do not repeat it.

What GLP-1 patients actually reported

This is the half of the week that gets the least attention and probably deserves the most.

Of ten side-effect posts on Reddit, four described fatigue severe enough to dominate daily life — and the cluster around them is not nausea. It is flatness.

• Three weeks in, on 2.5 mg: "I barely have any energy to walk long distances let alone exercise. I eat well. I drink water. I sleep 7-9 hours." Bloods checked, not anaemic. Resting heart rate climbing to 80.
• Thirteen months in, a family member "basically hypersomnic — sleeping 14 hours a day quite often, moody and just experiencing lassitude that seems worse for the three days following the shot." Weight loss had stalled, bloods still imperfect. The doctor's advice was to stick it out.
• On semaglutide, 2.5 months: "The level of fatigue is something i never experienced. And it's not getting any better with time."
• Six weeks in: "I am so quiet these days... I'm no longer talkative, and chatty... I do feel very tired, and drained. Can mounjaro affect your personality? I have zero sex drive as well."
• Shot #5, a bipolar patient whose psychiatrist raised it unprompted: "GLP-1's cause you to lose interest in food... and you can also lose interest in everyday life, like hobbies, activities, socializing."

That last one is the most useful thing in the corpus, because a clinician named the mechanism the patients are circling. Several of these people are describing something closer to anhedonia and blunting than to tiredness — reduced interest, reduced talkativeness, lost libido, flatness that is not depression. It is under-documented, we have no trial data to offer on it, and we are not going to pretend otherwise. But five independent people described the same thing in one week.

Two separate notes on that thirteen-month post. Sustained fatigue at month thirteen with stalled weight loss is not a titration problem, and "stick it out" is not obviously the right advice. Also insomnia around injection day appeared separately, which sits oddly beside the hypersomnia reports and suggests more than one thing is going on.

The switching advice was wrong

In that thread, the doctor also said that with GLP-1s, "if one does work none do" — meaning no point switching agents.

That is contradicted by a randomised trial designed around exactly this question. SURPASS-SWITCH (Billings LK, et al. 2025. Ann Intern Med 178(5):609-619. PMID 40183678, NCT05564039) randomised 282 adults inadequately controlled on dulaglutide either to escalate dulaglutide or switch to tirzepatide. At week 40:

Treatment difference −0.77% HbA1c (95% CI −0.98 to −0.56) and −6.9 kg, both p<0.001. Serious adverse events comparable, 7.0% vs 7.2%. It was open-label, which is its main limitation.

Switching works within the class too: SWITCH-SEMA 1 randomised patients on liraglutide or dulaglutide to switch to weekly semaglutide or continue, and HbA1c fell only in the switch arms (PMID 36722623).

And it is not one-directional. A 2026 case report describes a patient with under 5% weight loss despite escalation to tirzepatide 15 mg over six months, who then lost 20% over six months on semaglutide (PMID 42670558). One case is one case — but it falsifies the universal claim, and it also punctures the assumption that the more potent agent always wins.

Non-response, defined as under 5% total body weight loss, affects roughly 10% of trial participants and more in real-world cohorts, and no baseline characteristic reliably predicts it (PMID 42634284).

One framing correction, because this error is everywhere: SURMOUNT-5 is not switching evidence. It found tirzepatide −20.2% versus semaglutide −13.7% over 72 weeks (PMID 40353578), but it is a de novo head-to-head randomisation reporting no outcomes in prior non-responders. It tells you which drug is better on average. It does not tell you that a semaglutide non-responder will respond to tirzepatide. Cite SURPASS-SWITCH for that.

Honest limit: we found no direct trial evidence that someone who cannot tolerate one agent will tolerate another. Tolerability-driven switching is standard practice and pharmacologically plausible, since the agents differ in receptor profile and titration granularity. But that is reasoning, not data, and we are not going to dress it up as data.

Supply integrity: two concrete findings

Away from the claims, two posts did real work.

Underdosing, measured. One account sent product from a "supposedly reliable drop shipper" for third-party testing and published the results: retatrutide labelled 10 mg came back at 5 mg. Tesamorelin labelled 10 mg came back at 5 mg. A "Klow" blend labelled 80 mg came back as 116 mg of GHK-Cu alone. Their read: "giving you half of what you order so it'll still work but they're tripling their revenue." That is one buyer's test of one shipment and should be treated as such — but the pattern of a half-strength product that still produces some effect is a commercially rational fraud, which is what makes it worth naming.

The Aib question, which is sharper than it looks. A post on 17 September reported that a manufacturer allegedly said it "removes Aib from retatrutide but that the long-term effects remain the same," and asked whether routine testing would catch it.

The manufacturer conversation is second-hand and we could not corroborate it. The chemistry question is excellent, and the answer is worse than the poster suggested.

Retatrutide contains Aib at positions 2 and 20 (from the cryo-EM structure, PDB 8YW3; corroborated in PMID 39019866). Aib is a non-proteinogenic residue placed at the DPP-4 cleavage site to block degradation — the classic demonstration found Aib-substituted GLP-1 showed undetectable degradation after 6 hours versus a 28-minute half-life for native GLP-1 (PMID 9541166). Tirzepatide uses Aib at 2 and 13; semaglutide at position 2 of the analogue; liraglutide does not use Aib at all and is a DPP-4 substrate.

Retatrutide is built on the GIP backbone, and native GIP begins Tyr1-Ala2 — the canonical DPP-4 motif. So reverting Aib2 to Ala restores a cleavable N-terminus. And Tyr1 is load-bearing for agonism at all three receptors, so the cleaved product would be largely inactive at GLP-1R, GIPR and GCGR.

Here is the part that makes "the long-term effects remain the same" not merely unproven but backwards. Retatrutide's multi-day dosing interval comes mainly from the fatty-diacid acylation at Lys17 binding albumin, not from Aib. An Aib-stripped analogue could therefore still circulate for days while being enzymatically decapitated and pharmacologically inert — normal-looking pharmacokinetics, no effect.

Would a COA catch it?

That last row is the one to worry about. 2-aminobutyric acid is isomeric with Aib — both C₄H₇NO, both exactly 85.0528 Da — and Abu at position 2 is a documented design choice that, on a GIP backbone specifically, gives poor DPP-4 protection and weak activity (PMID 15246869). An Aib→Abu swap is invisible to intact mass. Distinguishing it needs MS/MS with good site coverage, amino-acid analysis, or co-elution against a qualified reference standard.

And an HPLC purity figure — the single number most grey-market COAs lead with — catches none of these. Purity reports homogeneity, not identity. A cleanly synthesised wrong molecule is 99% pure.

Also worth naming

The "peptide challenge." One post, 34 likes: "1) pin 5mg Reta 2) pin 1mg mt2 3) no carbs for 48 hours 4) pin 10mg MotsC (ouch) 5) 1mg DSIP in the morning. Only the strongest soldiers will be able to do this. If you don't die, you win 🤣." It is framed as a joke. 5 mg of retatrutide is well above any studied starting dose, stacked with melanotan-II and a 48-hour carbohydrate fast. We are noting it because "if you don't die, you win" is a punchline that describes the actual risk accurately.

A vendor's economics. A seller reported losing $55,000 trying to enter the business — "customs seizures, fake products from china, lab testing costs, legal, operating fees, payment processors running with your money." Useful context for why cheap product is cheap.

A vulnerable-user pattern. A 23-year-old with hypothyroidism and fatigue asked r/Peptides whether SS-31 would help, listing seven compounds he was considering stacking: MOTS-c, thymosin alpha-1, kisspeptin-10, epitalon, DSIP, selank, Adamax. Nobody in that thread asked whether his thyroid replacement was optimised first.

A GHK-Cu injection reaction. A user reported red raised patches persisting several days after using KLOW then GHK-Cu, mildly itchy, appearing the day after each injection. We have an article on GHK-Cu injection-site reactions and this is the second week running that this has come up. We should say plainly: we found no PubMed-indexed study of GHK-Cu injection-site reactions at all. Anyone citing one is citing something else.

Limitations

Our Reddit ingest is heavily weighted to r/Mounjaro (124 of 138 posts), so the GLP-1 share of "what was discussed" is partly a sampling artefact rather than a finding. X coverage is drawn from a curated influencer list, which over-represents large accounts and therefore over-represents confident claims. Engagement counts were captured at ingest and will have moved since.

Everything attributed to a Reddit or X user in this article is an anecdote. We quote them because what people report matters and because several reports converged, not because they constitute evidence. Where we have trial data we have said so and cited it; where we do not, we have said that instead.

Two specific things we could not verify and have flagged in place: WADA's official 2026 Prohibited List PDF (the site blocks document fetches), and the C-terminal extension of retatrutide's published sequence beyond residue 30, which appears in vendor datasheets but which we could not confirm against a primary or regulatory document.

The bottom line

BPC-157 dominated the week on the strength of five real studies described as though they were human. They are four rat studies and one rabbit study, the eyeball and spinal cord claims misstate both the injury and the timeline, 77% of the entire literature comes from one laboratory, and human exposure totals under thirty people in three uncontrolled reports. A real Phase 2 trial with an MRI endpoint is now recruiting and reports in about eighteen months, which is the first time that argument will have data behind it.

The dihexa post is a different category of problem. Claiming "good humans safety data" for a compound with zero human studies, whose mechanism papers were retracted last year for image manipulation, and whose proposed target is a validated oncogenic driver, is not exaggeration. It is an inversion.

And the week's best-described science was a viral thread that mostly got a Nature paper right. That is worth saying out loud, because the failure mode here is not that everything on social media is wrong. It is that the accurate and the fabricated arrive in the same format, with the same confidence, and the only thing that separates them is whether you check.

Related on this site

• Tesamorelin cannot give you abs, and the reason is anatomical
• The mouse study everyone got wrong
• BPC-157: animal versus human evidence
• Dihexa: an honest review
• How to read a peptide COA
• Peptide evidence grades

References

• Krivic A, Anic T, Seiwerth S, et al. 2006. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 24(5):982-9. PMID 16583442
• Perovic D, Kolenc D, Bilic V, et al. 2019. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 14(1):199. PMID 31266512
• Cerovecki T, Bojanic I, Brcic L, et al. 2010. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 28(9):1155-61. PMID 20225319
• Masnec S, Kokot A, Zlatar M, et al. 2015. Perforating corneal injury in rat and pentadecapeptide BPC 157. Exp Eye Res. 136:9-15. PMID 25912999
• Sebecić B, Nikolić V, Sikirić P, et al. 1999. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits. Bone. 24(3):195-202. PMID 10071911
• Barisic I, Balenovic D, Klicek R, et al. 2013. Mortal hyperkalemia disturbances in rats are NO-system related. The life saving effect of pentadecapeptide BPC 157. Regul Pept. 181:50-66. PMID 23327997
• Enache A. 2026. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 18(5):625. PMID 42198317
• McGuire FP, et al. 2025. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 18(12):611-619. PMID 40789979
• Lee E, Padgett B. 2021. Altern Ther Health Med. 27(4):8-13. PMID 34324435
• Lee E, Walker C, Ayadi B. 2024. Altern Ther Health Med. 30(10):12-17. PMID 39325560
• Lee E, Burgess K. 2025. Altern Ther Health Med. 31(5):20-24. PMID 40131143
• Feng Y, Barthez M, Wang Y, et al. 2026. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 657(8131):469-476. PMID 42686906
• Benoist CC, Kawas LH, et al. 2014. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 351(2):390-402. PMID 25187433 — RETRACTED April 2025
• Retraction notice to the above. J Pharmacol Exp Ther. 2025;392(4):103567. PMID 40312093
• McCoy AT, et al. 2013. J Pharmacol Exp Ther. 344(1):141-54. PMID 23055539 — expression of concern 2021
• Sun X, et al. 2021. Dihexa rescues cognition in an APP/PS1 mouse model via PI3K/AKT. Brain Sci. 11(11):1487. PMID 34827486
• Falutz J, Mamputu JC, Potvin D, et al. 2010. Effects of tesamorelin on visceral adipose tissue: pooled phase 3 analysis. J Clin Endocrinol Metab. 95(9):4291-304. PMID 20554713
• Makimura H, Feldpausch MN, Rope AM, et al. 2012. J Clin Endocrinol Metab. 97(12):4769-79. PMID 23015655
• Badran AS, Helal A, Shata KS, et al. 2026. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 20(1):2-12. PMID 41545261
• Gastaldelli A, Cusi K, Fernández Landó L, et al. 2022. Lancet Diabetes Endocrinol. 10(6):393-406. PMID 35468325
• Look M, Dunn JP, Kushner RF, et al. 2025. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 27(5):2720-2729. PMID 39996356
• Billings LK, Winne L, Sharma P, et al. 2025. Tirzepatide versus dulaglutide escalation in type 2 diabetes inadequately controlled on dulaglutide (SURPASS-SWITCH). Ann Intern Med. 178(5):609-619. PMID 40183678
• Takahashi Y, Nomoto H, Yokoyama H, et al. 2023. SWITCH-SEMA 1. Diabetes Obes Metab. 25(6):1503-1511. PMID 36722623
• La Vignera S, Condorelli RA. 2026. Tirzepatide non-response with subsequent semaglutide response in class 2 obesity. JCEM Case Rep. 4(9):luag245. PMID 42670558
• Kuryłowicz A, Czupryniak L. 2026. Responders vs. non-responders, or how to predict the response to GLP-1 or GLP-1/GIP receptor agonist therapy. Diabetes Obes Metab. Online ahead of print. PMID 42634284
• Aronne LJ, Horn DB, le Roux CW, et al. 2025. Tirzepatide versus semaglutide (SURMOUNT-5). N Engl J Med. 393(1):26-36. PMID 40353578
• Li W, Zhou Q, Cong Z, et al. 2024. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discov. 10(1):77. PMID 39019866
• Coskun T, Urva S, Roell WC, et al. 2022. Cell Metab. 34(9):1234-1247.e9. PMID 35985340
• Deacon CF, Knudsen LB, Madsen K, et al. 1998. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia. 41(3):271-8. PMID 9541166
• Green BD, Gault VA, Flatt PR, et al. 2004. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys. 428(2):136-43. PMID 15246869
• Carneiro GRA, et al. 2026. LC-HRMS detection of retatrutide for anti-doping. Rapid Commun Mass Spectrom. 40(23):e70179. PMID 42745421
• Beach R, Tims-Cook Z, McGary CS, et al. 2026. Clin Infect Dis. 82(Suppl 4):S87-S91. PMID 42139091
• Sikiric P, et al. 1993. J Physiol Paris. 87:313-327. PMID 8298609
• FDA. EMRELIS (telisotuzumab vedotin-tllv) accelerated approval, 14 May 2025. LUMINOSITY, NCT03539536
• ClinicalTrials.gov: NCT07437547 (BPC-157 Phase 2, hamstring strain), NCT07803250 (BPC-157 Phase 1, rotator cuff), NCT05564039 (SURPASS-SWITCH)
• PDB 8YW3 — retatrutide–GLP-1R–Gs cryo-EM structure